Leap Therapeutics FY2022 net loss $54.6M; cash $65.5M plus $50M from Flame acquisition

CYPHERPUNK TECHNOLOGIES INC.

Net loss $54.6M for 2022 (vs $40.6M in 2021); R&D expenses $45M (vs $32.2M).
Cash $65.5M at Dec 31, 2022; excludes ~$50M cash from Flame acquisition in Jan 2023.
Flame acquisition: issued ~19.8M common shares + 136.8k preferred convertible into 136.8M common shares (subject to approval).
DKN-01: Part C DisTinGuish randomized trial enrollment expected completion late 2023; Part A DeFianCe CRC study enrollment near completion.
BeiGene's option for DKN-01 in Asia expired; clinical collaboration continues for DisTinGuish Part C.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYPHERPUNK TECHNOLOGIES INC. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 24, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-036246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.